Recent discoveries have implicated the gut microbiome in the progression and severity of Parkinson’s disease; however, how gut bacteria affect such neurodegenerative disorders remains unclear. Here, we report that the Bacillus subtilis probiotic strain PXN21 inhibits a synuclein aggregation and clears preformed aggregates in an established Caenorhabditis elegans model of synucleinopathy. CLICK TO REVIEW